Across TCGA pan-cancer cohorts, MUCL3 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MUCL3 data layer compared with 21 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MUCL3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MUCL3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.
PDAC are the cancer types where MUCL3 mass-spec protein most reproducibly stratifies survival.